ClinicalTrials.gg
CompletedNCT05633992Updated Oct 2, 2024Results posted

Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)

A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 8 sites in Japan. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
8th of 10
450 · median 1,075
Started
2023
with 1 other
Phase 3
9 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 6th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve Japanese adults 65 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23 and the cross-reactive serotype 15B in V116, and that the immunogenicity of V116 is superior to PPSV23 for the unique serotype 15C in V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in the 8 unique V116 serotypes (except for 15C), as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is Japanese
  • For females, is not pregnant or breastfeeding and is either not a participant of (POCBP) or is a POCBP and uses acceptable /abstinence; has a negative highly sensitive pregnancy test (urine or serum) within 24 (urine) or 72 (serum) hours before the first dose of study intervention; and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease the chance of inclusion of an early undetected pregnancy

Exclusion criteria

Exclusion Criteria:

  • Has a history of invasive pneumococcal disease (IPD) [positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site] or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1)
  • Has a known to any component of V116 or PPSV23, including diphtheria toxoid
  • Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented (HIV) infection, functional or anatomic asplenia, or history of disease
  • Has a coagulation disorder contraindicating IM vaccination
  • Had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring \<72 hours before receipt of study vaccine
  • Has a known that is progressing or has required active treatment \<3 years before enrollment
  • Received prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol
  • Received systemic (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine
  • Is currently receiving therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
  • Received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤30 days after receipt of study vaccine (inactivated influenza and SARS-CoV2 vaccines may be acceptable)
  • Received any ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine
  • Received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    V116

    Participants receive a single intramuscular (IM) injection of V116 on Day 1.

    Biological: V116

  • Active comparator
    PPSV23

    Participants receive a single IM injection of PPSV23 on Day 1.

    Biological: PPSV23

Interventions

  • BiologicalV116

    Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPPSV23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.

    Also known as: PNEUMOVAX™23

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.

    Time frame: Up to 5 days postvaccination

  2. Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited systemic AEs were muscle pain/myalgia, headache, and tiredness/fatigue.

    Time frame: Up to 5 days postvaccination

  3. Percentage of Participants With Vaccine-related Serious AEs (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were summarized.

    Time frame: Up to 30 days postvaccination

  4. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)

    The serotype-specific OPA GMTs for the 12 common serotypes contained in V116 and PPSV23, the unique serotype 15C in V116, and the cross-reactive serotype 15B were determined using the multiplex opsonophagocytic assay (MOPA).

    Time frame: Day 30 postvaccination

  5. Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)

    The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the 8 unique serotypes contained in V116 (except for 15C) were determined.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

Secondary outcomes

  1. Serotype-specific OPA GMTs (Unique Serotypes)

    The serotype-specific OPA GMTs for the 8 unique serotypes contained in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116 were determined using MOPA.

    Time frame: Day 30 postvaccination

  2. Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs)

    The GMCs for serotype-specific IgG antibodies were determined using pneumococcal electrochemiluminescence (PnECL).

    Time frame: Day 30 postvaccination

  3. Serotype-specific Geometric Mean Fold Rise (GMFR) in OPA GMT

    The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  4. Serotype-specific GMFR in IgG GMCs

    The GMFR from baseline in GMCs for serotype-specific IgG antibodies was determined using PnECL. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  5. Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPA GMTs (All Serotypes)

    Activity for the serotypes contained in V116 and PPSV23 were determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  6. Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific IgG GMCs (All Serotypes)

    Activity for the serotypes contained in V116 and PPSV23 were determined using PnECL. The percentage of participants who had ≥4-fold rise in IgG titers were calculated from baseline to postvaccination.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

07

Results

Posted May 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneV116PPSV23
Started225225
Completed225225
Not completed00

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-site Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.

Time frame:
Up to 5 days postvaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
Percentage of participantsV116PPSV23
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)32.939.1
PrimaryPercentage of Participants With Solicited Systemic AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited systemic AEs were muscle pain/myalgia, headache, and tiredness/fatigue.

Time frame:
Up to 5 days postvaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Systemic AEs
Percentage of participantsV116PPSV23
Percentage of Participants With Solicited Systemic AEs17.316.4
PrimaryPercentage of Participants With Vaccine-related Serious AEs (SAEs)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were summarized.

Time frame:
Up to 30 days postvaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine-related Serious AEs (SAEs)
Percentage of participantsV116PPSV23
Percentage of Participants With Vaccine-related Serious AEs (SAEs)0.00.0
PrimarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)

The serotype-specific OPA GMTs for the 12 common serotypes contained in V116 and PPSV23, the unique serotype 15C in V116, and the cross-reactive serotype 15B were determined using the multiplex opsonophagocytic assay (MOPA).

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · Titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)
TitersV116PPSV23
Day 30, Serotype 3155.1 (133.6 to 180.1)170.8 (143.9 to 202.9)
Day 30, Serotype 7F2675.1 (2312.9 to 3094.0)2411.4 (2054.5 to 2830.2)
Day 30, Serotype 81293.3 (1133.8 to 1475.2)1142.4 (988.3 to 1320.4)
Day 30, Serotype 9N2844.8 (2492.7 to 3246.6)2710.5 (2297.6 to 3197.6)
Day 30, Serotype 10A1591.2 (1367.4 to 1851.7)880.2 (690.1 to 1122.6)
Day 30, Serotype 11A1269.6 (1057.6 to 1524.1)887.9 (748.3 to 1053.4)
Day 30, Serotype 12F968.5 (792.5 to 1183.6)503.7 (383.8 to 661.0)
Day 30, Serotype 17F3138.1 (2673.0 to 3684.2)1860.3 (1551.8 to 2230.1)
Day 30, Serotype 19A1338.4 (1144.3 to 1565.4)1140.7 (925.1 to 1406.5)
Day 30, Serotype 20A2617.2 (2212.9 to 3095.5)1731.5 (1474.1 to 2033.7)
Day 30, Serotype 22F1830.9 (1562.4 to 2145.6)1295.5 (1072.6 to 1564.8)
Day 30, Serotype 33F7692.4 (6349.4 to 9319.4)8610.8 (7029.9 to 10547.1)
Day 30, Serotype 15C2488.5 (1993.5 to 3106.6)1185.0 (954.1 to 1471.7)
Day 30, Serotype 15B2081.1 (1675.0 to 2585.7)1479.7 (1218.0 to 1797.5)
Baseline, Serotype 314.2 (12.5 to 16.1)14.9 (13.1 to 17.0)
Baseline, Serotype 7F243.9 (190.8 to 311.7)217.6 (168.8 to 280.4)
Baseline, Serotype 848.8 (38.3 to 62.3)46.3 (36.7 to 58.5)
Baseline, Serotype 9N383.1 (313.3 to 468.4)383.2 (314.6 to 466.8)
Baseline, Serotype 10A131.5 (101.3 to 170.6)103.5 (77.4 to 138.5)
Baseline, Serotype 11A75.2 (55.9 to 101.3)91.2 (68.3 to 121.7)
Baseline, Serotype 12F18.1 (14.7 to 22.3)19.2 (15.6 to 23.7)
Baseline, Serotype 17F285.8 (225.7 to 361.8)226.8 (181.0 to 284.1)
Baseline, Serotype 19A188.1 (151.9 to 232.8)179.7 (143.4 to 225.1)
Baseline, Serotype 20A460.0 (384.4 to 550.6)421.1 (348.9 to 508.1)
Baseline, Serotype 22F179.9 (138.0 to 234.7)167.9 (128.0 to 220.3)
Baseline, Serotype 33F1236.7 (1048.1 to 1459.3)1198.9 (1004.3 to 1431.3)
Baseline, Serotype 15C110.0 (85.2 to 142.1)102.6 (79.4 to 132.4)
Baseline, Serotype 15B243.3 (194.6 to 304.1)251.7 (199.7 to 317.2)
Statistical analysis
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 0.94 · 95% CI 0.75 to 1.17Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.08 · 95% CI 0.88 to 1.33Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.12 · 95% CI 0.93 to 1.36Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.05 · 95% CI 0.86 to 1.29Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.65 · 95% CI 1.28 to 2.14Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.52 · 95% CI 1.20 to 1.92Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.97 · 95% CI 1.43 to 2.72Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.60 · 95% CI 1.28 to 2.00Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.16 · 95% CI 0.93 to 1.45Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.44 · 95% CI 1.18 to 1.77Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.39 · 95% CI 1.10 to 1.76Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 0.87 · 95% CI 0.68 to 1.12Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 1.43 · 95% CI 1.07 to 1.89Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
  • V116 vs PPSV23 · Constrained Longitudinal Data Analysis · p = <0.001 · Day 30 gmt ratio: 2.05 · 95% CI 1.56 to 2.70Ratio is V116/PPSV23. GMT ratio and confidence interval estimated from the cLDA model. The cLDA model-based ratio includes estimated data for participants who had baseline data available but no day 30 measurement.
PrimaryPercentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)

The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the 8 unique serotypes contained in V116 (except for 15C) were determined.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)
Percentage of ParticipantsV116PPSV23
Serotype 6A72.845.3
Serotype 15A59.726.0
Serotype 16F50.311.9
Serotype 23A57.627.9
Serotype 23B82.143.7
Serotype 24F42.916.0
Serotype 3170.313.1
Serotype 35B52.96.0
Statistical analysis
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 27.6 · 95% CI 17.8 to 36.9Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 33.7 · 95% CI 23.6 to 43.0Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 38.3 · 95% CI 29.8 to 46.4Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 29.5 · 95% CI 17.4 to 40.6Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 38.3 · 95% CI 29.3 to 46.7Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 27.1 · 95% CI 18.3 to 35.6Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 57.3 · 95% CI 49.3 to 64.4Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
  • V116 vs PPSV23 · Stratified Miettinen & Nurminen · p = <0.001 · Difference in percent: 47.0 · 95% CI 39.5 to 54.1Estimated difference and confidence interval are based on the Miettinen \& Nurminen method.
SecondarySerotype-specific OPA GMTs (Unique Serotypes)

The serotype-specific OPA GMTs for the 8 unique serotypes contained in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116 were determined using MOPA.

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · Titers
Serotype-specific OPA GMTs (Unique Serotypes)
TitersV116PPSV23
Serotype 6A1263.8 (1036.6 to 1540.7)641.8 (507.0 to 812.4)
Serotype 15A2752.3 (2319.8 to 3265.5)832.2 (687.4 to 1007.6)
Serotype 16F4094.8 (3574.8 to 4690.4)1183.9 (987.2 to 1419.7)
Serotype 23A2107.5 (1702.3 to 2609.1)729.2 (556.8 to 955.0)
Serotype 23B1359.0 (1086.7 to 1699.5)202.2 (146.5 to 279.2)
Serotype 24F2521.9 (2246.2 to 2831.4)1043.8 (878.1 to 1240.7)
Serotype 312095.4 (1746.3 to 2514.2)260.7 (200.9 to 338.2)
Serotype 35B4758.1 (4146.5 to 5459.9)1051.4 (886.6 to 1246.9)
SecondarySerotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs)

The GMCs for serotype-specific IgG antibodies were determined using pneumococcal electrochemiluminescence (PnECL).

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · µg/mL
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs)
µg/mLV116PPSV23
Serotype 30.54 (0.47 to 0.61)0.58 (0.51 to 0.67)
Serotype 7F6.12 (5.13 to 7.31)4.25 (3.50 to 5.14)
Serotype 88.13 (7.01 to 9.42)6.72 (5.87 to 7.71)
Serotype 9N7.49 (6.23 to 9.01)5.44 (4.55 to 6.50)
Serotype 10A8.21 (6.64 to 10.15)3.84 (3.09 to 4.79)
Serotype 11A6.00 (5.09 to 7.08)3.02 (2.59 to 3.52)
Serotype 12F1.55 (1.23 to 1.95)0.66 (0.52 to 0.84)
Serotype 17F10.48 (8.77 to 12.52)5.08 (4.32 to 5.98)
Serotype 19A5.70 (4.80 to 6.76)4.87 (4.07 to 5.83)
Serotype 20A15.61 (13.20 to 18.47)9.78 (8.09 to 11.83)
Serotype 22F2.84 (2.28 to 3.52)1.39 (1.14 to 1.69)
Serotype 33F13.93 (11.92 to 16.27)12.67 (10.90 to 14.74)
Serotype 6A3.42 (2.74 to 4.26)1.64 (1.33 to 2.02)
Serotype 15A9.98 (8.14 to 12.25)1.64 (1.35 to 1.98)
Serotype 15C9.87 (7.95 to 12.26)4.55 (3.69 to 5.60)
Serotype 16F3.07 (2.56 to 3.68)0.37 (0.31 to 0.43)
Serotype 23A2.00 (1.60 to 2.51)0.32 (0.27 to 0.39)
Serotype 23B4.22 (3.58 to 4.99)1.65 (1.37 to 1.98)
Serotype 24F7.79 (6.26 to 9.71)0.41 (0.35 to 0.47)
Serotype 312.57 (2.16 to 3.07)0.40 (0.34 to 0.46)
Serotype 35B14.19 (12.01 to 16.76)1.38 (1.19 to 1.60)
Serotype 6C1.19 (0.97 to 1.46)0.50 (0.42 to 0.59)
Serotype 15B10.15 (8.35 to 12.35)9.86 (8.40 to 11.59)
SecondarySerotype-specific Geometric Mean Fold Rise (GMFR) in OPA GMT

The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Geometric mean · Ratio
Serotype-specific Geometric Mean Fold Rise (GMFR) in OPA GMT
RatioV116PPSV23
Serotype 37.2 (6.1 to 8.5)7.2 (6.1 to 8.5)
Serotype 7F10.0 (8.0 to 12.6)9.8 (8.0 to 12.1)
Serotype 820.6 (16.4 to 25.8)19.1 (15.5 to 23.7)
Serotype 9N6.9 (5.6 to 8.5)6.6 (5.3 to 8.1)
Serotype 10A10.1 (8.2 to 12.4)7.6 (5.9 to 9.9)
Serotype 11A13.6 (10.5 to 17.7)7.3 (5.7 to 9.4)
Serotype 12F32.2 (25.7 to 40.3)17.1 (13.2 to 22.1)
Serotype 17F9.8 (7.8 to 12.4)7.1 (5.9 to 8.6)
Serotype 19A6.7 (5.5 to 8.1)5.8 (4.8 to 6.9)
Serotype 20A5.6 (4.7 to 6.6)4.1 (3.4 to 4.8)
Serotype 22F8.9 (6.9 to 11.5)6.9 (5.4 to 8.8)
Serotype 33F6.4 (5.2 to 7.8)7.3 (6.0 to 8.8)
Serotype 6A9.4 (7.5 to 11.6)3.7 (3.0 to 4.5)
Serotype 15A6.7 (5.3 to 8.5)2.0 (1.6 to 2.4)
Serotype 15C19.1 (15.2 to 24.1)9.3 (7.4 to 11.7)
Serotype 16F4.7 (4.0 to 5.6)1.5 (1.4 to 1.7)
Serotype 23A5.9 (4.2 to 8.2)1.8 (1.4 to 2.4)
Serotype 23B26.2 (20.5 to 33.6)4.2 (3.3 to 5.4)
Serotype 24F3.8 (3.1 to 4.6)1.5 (1.2 to 1.8)
Serotype 3113.6 (10.6 to 17.3)1.4 (1.2 to 1.6)
Serotype 35B5.5 (4.6 to 6.5)1.2 (1.0 to 1.3)
Serotype 6C2.9 (2.4 to 3.7)2.0 (1.7 to 2.3)
Serotype 15B7.4 (5.7 to 9.5)4.8 (3.7 to 6.2)
SecondarySerotype-specific GMFR in IgG GMCs

The GMFR from baseline in GMCs for serotype-specific IgG antibodies was determined using PnECL. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Geometric mean · Ratio
Serotype-specific GMFR in IgG GMCs
RatioV116PPSV23
Serotype 35.0 (4.5 to 5.7)5.1 (4.5 to 5.8)
Serotype 7F12.1 (10.2 to 14.3)8.3 (7.1 to 9.7)
Serotype 811.6 (9.8 to 13.7)9.8 (8.4 to 11.3)
Serotype 9N11.8 (9.8 to 14.3)9.8 (8.4 to 11.5)
Serotype 10A11.4 (9.7 to 13.4)6.4 (5.5 to 7.4)
Serotype 11A8.0 (6.8 to 9.4)3.9 (3.5 to 4.4)
Serotype 12F11.9 (9.8 to 14.6)6.3 (5.2 to 7.5)
Serotype 17F12.9 (10.9 to 15.2)7.0 (6.1 to 8.1)
Serotype 19A5.1 (4.3 to 5.9)4.2 (3.7 to 4.9)
Serotype 20A9.5 (8.1 to 11.2)6.2 (5.4 to 7.2)
Serotype 22F10.7 (8.9 to 12.9)5.7 (4.8 to 6.6)
Serotype 33F8.7 (7.4 to 10.2)7.7 (6.6 to 8.9)
Serotype 6A10.4 (8.7 to 12.5)4.1 (3.6 to 4.7)
Serotype 15A14.0 (11.8 to 16.5)2.7 (2.4 to 3.1)
Serotype 15C14.3 (11.8 to 17.3)6.9 (5.9 to 8.1)
Serotype 16F12.8 (11.0 to 14.9)1.6 (1.5 to 1.7)
Serotype 23A12.0 (10.1 to 14.4)2.0 (1.8 to 2.2)
Serotype 23B8.6 (7.5 to 10.0)3.1 (2.8 to 3.5)
Serotype 24F18.0 (15.2 to 21.2)1.1 (1.0 to 1.1)
Serotype 319.1 (8.0 to 10.5)1.5 (1.3 to 1.6)
Serotype 35B12.7 (10.8 to 14.8)1.1 (1.0 to 1.1)
Serotype 6C2.7 (2.3 to 3.2)1.3 (1.2 to 1.4)
Serotype 15B6.8 (5.7 to 8.2)7.3 (6.3 to 8.6)
SecondaryPercentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPA GMTs (All Serotypes)

Activity for the serotypes contained in V116 and PPSV23 were determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPA GMTs (All Serotypes)
Percentage of ParticipantsV116PPSV23
Serotype 373.8 (66.9 to 79.9)71.3 (64.4 to 77.5)
Serotype 7F68.5 (61.9 to 74.7)69.6 (63.0 to 75.6)
Serotype 879.8 (73.8 to 85.0)81.0 (75.1 to 86.1)
Serotype 9N57.6 (50.0 to 65.0)58.8 (51.1 to 66.1)
Serotype 10A69.3 (62.4 to 75.6)59.7 (52.4 to 66.7)
Serotype 11A69.3 (62.4 to 75.6)55.8 (48.6 to 62.9)
Serotype 12F84.3 (78.7 to 88.8)74.3 (67.7 to 80.1)
Serotype 17F66.1 (58.8 to 72.9)62.6 (55.3 to 69.5)
Serotype 19A58.1 (51.2 to 64.7)61.0 (54.1 to 67.6)
Serotype 20A54.1 (47.1 to 61.1)42.3 (35.3 to 49.6)
Serotype 22F62.0 (55.0 to 68.6)52.3 (45.1 to 59.4)
Serotype 33F58.0 (51.1 to 64.7)63.7 (56.9 to 70.2)
Serotype 6A72.8 (65.8 to 79.1)45.3 (38.0 to 52.6)
Serotype 15A59.7 (52.1 to 66.9)26.0 (19.6 to 33.3)
Serotype 15C81.0 (74.9 to 86.2)65.4 (58.2 to 72.2)
Serotype 16F50.3 (43.1 to 57.4)11.9 (7.8 to 17.2)
Serotype 23A57.6 (49.1 to 65.8)27.9 (19.8 to 37.2)
Serotype 23B82.1 (76.1 to 87.1)43.7 (36.7 to 50.9)
Serotype 24F42.9 (35.9 to 50.1)16.0 (10.9 to 22.3)
Serotype 3170.3 (63.8 to 76.3)13.1 (8.9 to 18.4)
Serotype 35B52.9 (46.1 to 59.7)6.0 (3.2 to 10.0)
Serotype 6C34.2 (27.6 to 41.1)25.4 (19.5 to 32.1)
Serotype 15B67.2 (60.0 to 73.9)54.6 (47.1 to 61.9)
SecondaryPercentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific IgG GMCs (All Serotypes)

Activity for the serotypes contained in V116 and PPSV23 were determined using PnECL. The percentage of participants who had ≥4-fold rise in IgG titers were calculated from baseline to postvaccination.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific IgG GMCs (All Serotypes)
Percentage of ParticipantsV116PPSV23
Serotype 356.4 (49.7 to 63.0)59.6 (52.8 to 66.0)
Serotype 7F77.8 (71.8 to 83.0)70.7 (64.2 to 76.5)
Serotype 878.7 (72.7 to 83.8)78.7 (72.7 to 83.8)
Serotype 9N72.9 (66.6 to 78.6)75.1 (68.9 to 80.6)
Serotype 10A79.1 (73.2 to 84.2)61.8 (55.1 to 68.2)
Serotype 11A69.3 (62.9 to 75.3)44.9 (38.3 to 51.6)
Serotype 12F73.3 (67.0 to 79.0)56.9 (50.1 to 63.5)
Serotype 17F82.7 (77.1 to 87.4)69.3 (62.9 to 75.3)
Serotype 19A49.3 (42.6 to 56.1)47.1 (40.4 to 53.9)
Serotype 20A75.1 (68.9 to 80.6)59.6 (52.8 to 66.0)
Serotype 22F71.6 (65.2 to 77.4)56.9 (50.1 to 63.5)
Serotype 33F71.6 (65.2 to 77.4)73.3 (67.0 to 79.0)
Serotype 6A76.4 (70.3 to 81.8)45.8 (39.1 to 52.5)
Serotype 15A80.9 (75.1 to 85.8)27.6 (21.8 to 33.9)
Serotype 15C77.8 (71.8 to 83.0)61.3 (54.6 to 67.7)
Serotype 16F80.4 (74.7 to 85.4)8.0 (4.8 to 12.4)
Serotype 23A76.9 (70.8 to 82.2)14.7 (10.3 to 20.0)
Serotype 23B72.9 (66.6 to 78.6)35.6 (29.3 to 42.2)
Serotype 24F87.6 (82.5 to 91.6)0.0 (0.0 to 1.6)
Serotype 3175.6 (69.4 to 81.0)7.6 (4.5 to 11.8)
Serotype 35B84.0 (78.5 to 88.5)0.9 (0.1 to 3.2)
Serotype 6C29.8 (23.9 to 36.2)6.7 (3.8 to 10.8)
Serotype 15B60.4 (53.7 to 66.9)65.3 (58.7 to 71.5)

Adverse events

Collected over Up to approximately 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V1160/225 (0%)1/225 (0.4%)77/225 (34.2%)
PPSV230/225 (0%)0/225 (0%)96/225 (42.7%)
Most frequent serious events
Most frequent serious events
EventV116PPSV23
Lacunar infarctionNervous system disorders1/2250/225
Most frequent other events
Most frequent other events
EventV116PPSV23
Injection site painGeneral disorders60/22581/225
FatigueGeneral disorders15/22525/225
Injection site erythemaGeneral disorders19/22524/225
Injection site swellingGeneral disorders14/22517/225

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V116PPSV23Total
Mean70.9 ± 5.770.9 ± 5.670.9 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)V116PPSV23Total
Female9996195
Male126129255
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V116PPSV23Total
Hispanic or Latino000
Not Hispanic or Latino225225450
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V116PPSV23Total
American Indian or Alaska Native000
Asian225225450
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT)
Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT)(Titers)V116PPSV23Total
Serotype 6A108.5 (19.5 to 3133)149.1 (19.5 to 9061)127.9 (19.5 to 9061)
Serotype 15A387.0 (21.0 to 9904)416.4 (21.0 to 9477)401.3 (21.0 to 9904)
Serotype 16F820.5 (78.0 to 25880)757.9 (78.0 to 25880)787.8 (78.0 to 175891)
Serotype 23A324.0 (21.0 to 14131)344.8 (21.0 to 7126)333.9 (21.0 to 14131)
Serotype 23B36.6 (5.0 to 4303)41.2 (5.0 to 4834)38.9 (5.0 to 4834)
Serotype 24F627.6 (10.5 to 10682)641.9 (10.5 to 8032)634.6 (10.5 to 10682)
Serotype 31129.0 (8.0 to 3765)176.5 (8.0 to 71474)151.0 (8.0 to 71474)
Serotype 35B852.6 (12.0 to 12052)937.0 (12.0 to 11378)893.7 (12.0 to 12052)
08

Study locations

8 sites
  • Medical Corporation Heishinkai OPHAC Hospital ( Site 1008)
    Osaka-shi, Osaka 532-0003, Japan
  • Medical Corporation Heishinkai OCROM Clinic ( Site 1003)
    Suita-shi, Osaka 565-0853, Japan
  • P-One Clinic ( Site 1001)
    Hachioji, Tokyo 192-0071, Japan
  • Heishinkai Medical Group ToCROM Clinic ( Site 1004)
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1006)
    Shinjuku-ku, Tokyo 160-0017, Japan
  • Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 1005)
    Toshima, Tokyo 171-0014, Japan
  • PS Clinic ( Site 1002)
    Fukuoka, 812-0025, Japan
  • Nishikumamoto Hospital ( Site 1007)
    Kumamoto, 861-4157, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2023, 4 months.

Results were first posted in May 2024, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Jan 10, 2023
Primary completionActual
May 24, 2023
CompletionActual
May 24, 2023
Results first posted
May 30, 2024
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05633992
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Jan 10, 2023
Primary completion
May 24, 2023
Completion
May 24, 2023
Results posted
May 30, 2024
Last update
Oct 2, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion